Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

TesamorelinExplore study findings

What a randomized extension showed when participants switched to placebo

2 numbered sourcesSource years 2010, 2026

Peptides are short chains of amino acids linked by peptide bonds. Some resemble the natural messages that regulate hormone release. Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with an added chemical group at its starting end. An older clinical trial used a second randomized phase to ask what happened to abdominal visceral fat when participants continued the study treatment or switched to placebo. [1, 2]

No recent primary report of this exact continuation and withdrawal comparison was identified. The older study enrolled 404 adults with HIV and excess abdominal fat in the context of antiretroviral treatment. In the first six months, participants were assigned to tesamorelin or placebo. The researchers used imaging to measure fat stored around internal organs. On average, visceral fat fell more in the tesamorelin group than in the placebo group during this first phase. [1]

In the extension, people initially receiving tesamorelin were assigned again, either to continue or to switch to placebo. The comparison helps distinguish an effect that persists after exposure ends from one that depends on continued exposure during the observation period. The investigators reported that reductions in visceral fat were maintained or deepened among participants who continued, while the initial changes were rapidly lost in the group that switched to placebo. [1]

The outcome was visceral fat measured with imaging. That result is different from an outcome for body weight or fat in other places. It also does not establish whether the observed differences would affect heart disease or other events years later. Those are separate questions that require longer follow-up and a study designed to capture them. [1, 2]

The original trial and its extension help explain the evidence behind the defined U.S. indication for excess abdominal fat in adults with HIV-associated lipodystrophy. The continuation and withdrawal results describe the study groups and observation period. They do not predict the course for every individual or provide evidence for general weight management. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Tesamorelin

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.